# 1.3 Pharmaceutical and Others

# Effective synthesis of [<sup>11</sup>C]PK11195 for clinical application by using loop method

K. Terasaki<sup>1</sup>, Y. Ishikawa<sup>2</sup>, T. Beppu<sup>3</sup>, M. Shozushima<sup>4</sup>, S. Goto<sup>5</sup> and R. Iwata<sup>2</sup>

<sup>1</sup>Cyclotron Research Center, Iwate Medical University 348-58 Tomegamori, Takizawa 020-0173, Japan

<sup>2</sup>CYRIC, Tohoku University Aramaki, Aoba-ku, Sendai 980-8579, Japan

<sup>3</sup>epartment of neurosurgery, Iwate Medical University 19-1 Uchimaru, Morioka, 020-8505, Japan

<sup>4</sup>Department of Dental Radiology, School of Dentistry, Iwate Medical University 19-1 Uchimaru, Morioka, 020-8505, Japan

<sup>5</sup>Japan Radioisotope Association, Nishina Memorial Cyclotron Center 348-58 Tomegamori, Takizawa 020-0173, Japan

### Abstract

 $[^{11}C]PK11195$  is a specific ligand for the peripheral type benzodiazepine receptor and a marker of activated microglia, used to measure inflammation in neurologic disorders. A simple, rapid and fully automated preparation of  $[^{11}C]PK11195$  was achieved with the automated methylation labelling system based on the loop method. To a solution desmethyl-PK11195 (1 mg) in MEK (60 µL) was added TBAOH (1 M in methanol, 6µL), and the solution loaded onto the loop.  $[^{11}C]MeOTf$  passed through the loop at room temperature. The products of the reaction were then transferred by passing mobile phase to a semi-preparative HPLC system. The method produced  $[^{11}C]PK11195$  in approximately 20 min after end of bombardment, with a 25-60% radiochemical yield (decay corrected yield from radioactivity trapped in the loop to isolated HPLC fraction). The final  $[^{11}C]PK11195$  activities are sufficient for several human PET. Moreover, the method can be successfully applied for routine clinical application, proved to be a simplified alternative to the bubbling method.

## Development of <sup>18</sup>F-labeled tumor imaging probes for clinical use

R. Iwata, K. Terasaki<sup>\*</sup> and Y. Ishikawa

Cyclotron and Radioisotope Center, Tohoku University 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan

\*Cyclotron Research Center, Iwate Medical University 348-58 Tomegamori, Takizawa, Iwate 020-0173, Japan

## Abstract

A collaborative study between Tohoku University and Iwate Medical University was initiated to develop a new <sup>18</sup>F-labeled tumor imaging probe at Nishina Memorial Cyclotron Center. Considering several <sup>18</sup>F-probes which are presently evaluated to be useful for clinical use in oncology, [<sup>18</sup>F]FRP-170, a potential hypoxic cell imaging agent which was originally developed at Tohoku University, was chosen as a candidate probe. Based on an automated module for [<sup>18</sup>F]FDG preparation, F100, a new automated system was developed by introducing a purification module consisting of a syringe pump module and an HPLC injector for on-column base hydrolysis followed by HPLC purification. The study is currently in progress.

# Cell cycle dependency of <sup>18</sup>F-Choline and <sup>18</sup>FDG uptake during proliferation of cultured human cancer cells

M. Shozushima, J. Yamamoto, Y. Hara<sup>1</sup>, K. Terasaki<sup>2</sup>, S. Goto<sup>3</sup> and R. Iwata<sup>4</sup>

Department of Dental Radiology, School of Dentistry, Iwate Medical University 19-1 Uchimaru, Morioka 020-8505, Japan

<sup>1</sup>Department of Oral Surgery, School of Dentistry, Iwate Medical University 19-1 Uchimaru, Morioka 020-8505, Japan

<sup>2</sup>Cyclotron Research Center, Iwate Medical University 348-58 Tomegamori, Takizawa, Iwate 020-0173, Japan

<sup>3</sup>Nishina Memorial Cyclotron Center, Takizawa Institute, Japan Radioisotope Association 348-58 Tomegamori, Takizawa, Iwate 020-0173, Japan

> <sup>4</sup>CYRIC Tohoku University Aramaki, Aoba-ku, Sendai 980-8579, Japan

### Abstract

In this study, the relationship between <sup>18</sup>F-Choline uptake and the cell cycle phase in cultured human cancer cells (HeLa S3), as well as how they compare to the conventional tracer <sup>18</sup>FDG with PET was assessed.

Flow cytometry findings confirmed that the cells were well synchronized. <sup>18</sup>F-Choline uptake was 77% of the peak level in the early S-phase immediately after release, gradually increased, and peaked in the early G2/M phase. Subsequently, <sup>18</sup>F-Choline uptake steeply declined over the late G2/M phase to 58% in the G1 phase. However, <sup>18</sup>FDG was significantly higher in the early S phase compared to the G1 phase.

The results suggest that the uptake of <sup>18</sup>F-Choline and <sup>18</sup>FDG are cell cycle dependent, are associated with the proliferative activity of the tumor seen during PET imaging.